Exploration of BioMat-X

From: Osimertinib nano-niosomes: surfactant effects, release kinetics, and cytotoxicity studies

Table 4. Comparative IC₅₀ values for free osimertinib and osimertinib-loaded nano-niosomal formulations (F1–F4) against KAIMRC-2, MDA-MB231, and HCT-116 cell lines.

Cell line	Treatment	Log IC₅₀	IC₅₀ (µg/mL)	R²	% Reduction vs. free OSI
KAIMRC-2	Free OSI	1.00	10.0	0.97	–
KAIMRC-2	F1 (Span 60)	0.85	7.1	0.97	29% ↓
KAIMRC-2	F2 (Tween 60)	0.77	5.9	0.92	41% ↓
KAIMRC-2	F3 (Pluronic F-127)	0.86	8.6	0.94	14% ↓
KAIMRC-2	F4 (Brij 52)	0.81	6.5	0.92	35% ↓
MDA-MB231	Free OSI	1.05	11.2	0.96	–
MDA-MB231	F1 (Span 60)	0.97	9.4	0.95	16% ↓
MDA-MB231	F2 (Tween 60)	0.95	9.7	0.94	13% ↓
MDA-MB231	F3 (Pluronic F-127)	0.90	8.0	0.96	29% ↓
MDA-MB231	F4 (Brij 52)	0.87	7.5	0.93	33% ↓
HCT-116	Free OSI	1.02	10.5	0.97	–
HCT-116	F1 (Span 60)	0.97	9.5	0.97	10% ↓
HCT-116	F2 (Tween 60)	0.99	9.9	0.98	6% ↓
HCT-116	F3 (Pluronic F-127)	0.71	5.1	0.95	51% ↓
HCT-116	F4 (Brij 52)	0.89	7.9	0.96	25% ↓

Return to article view

Declarations

Acknowledgments

The authors gratefully acknowledge the King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia, for generously providing the cell lines used in this study.

Author contributions

S Alhabardi: Conceptualization, Methodology, Investigation, Writing—original draft, Supervision, Project administration. A Almurshedi: Methodology, Investigation, Data curation, Writing—review & editing. S Alnassar: Formal analysis, Investigation, Writing—review & editing. S Alshabanah: Data curation, Visualization, Writing—review & editing. NA: Resources, Investigation. A Alotaibi: Validation, Data curation. LA: Software, Formal analysis. S Alahmari: Resources, Investigation. A Alanteet: Resources, Investigation. All authors have read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems--an overview. Adv Colloid Interface Sci. 2012;183–184:46–54. [DOI] [PubMed]

Ruckmani K, Sankar V. Formulation and optimization of Zidovudine niosomes. AAPS PharmSciTech. 2010;11:1119–27. [DOI] [PubMed] [PMC]

Moammeri A, Chegeni MM, Sahrayi H, Ghafelehbashi R, Memarzadeh F, Mansouri A, et al. Current advances in niosomes applications for drug delivery and cancer treatment. Mater Today Bio. 2023;23:100837. [DOI] [PubMed] [PMC]

Taymouri S, Varshosaz J. Effect of different types of surfactants on the physical properties and stability of carvedilol nano-niosomes. Adv Biomed Res. 2016;5:48. [DOI] [PubMed] [PMC]

Deulkar DA, Kubde JA, Hatwar PR, Bakal RL, Motwani AN. Niosomes: A promising approach for targeted drug delivery. GSC Biol Pharm Sci. 2024;29:179–95. [DOI]

Riccardi D, Baldino L, Reverchon E. Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field. J Transl Med. 2024;22:339. [DOI] [PubMed] [PMC]

Witika BA, Bassey KE, Demana PH, Siwe-Noundou X, Poka MS. Current Advances in Specialised Niosomal Drug Delivery: Manufacture, Characterization and Drug Delivery Applications. Int J Mol Sci. 2022;23:9668. [DOI] [PubMed] [PMC]

Lamb YN. Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC. Target Oncol. 2021;16:687–95. [DOI] [PubMed] [PMC]

Lin Y, Hsiao C, Alshetaili A, Aljuffali IA, Chen E, Fang J. Lipid-based nanoformulation optimization for achieving cutaneous targeting: Niosomes as the potential candidates to fulfill this aim. Eur J Pharm Sci. 2023;186:106458. [DOI] [PubMed]

10.

Gaikwad DS, Chougale RD, Patil KS, Disouza JI, Hajare AA. Design, development, and evaluation of docetaxel-loaded niosomes for the treatment of breast cancer. Futur J Pharm. 2023;9:43. [DOI]

11.

Liga S, Paul C, Moacă E, Péter F. Niosomes: Composition, Formulation Techniques, and Recent Progress as Delivery Systems in Cancer Therapy. Pharmaceutics. 2024;16:223. [DOI] [PubMed] [PMC]

12.

Nowroozi F, Almasi A, Javidi J, Haeri A, Dadashzadeh S. Effect of Surfactant Type, Cholesterol Content and Various Downsizing Methods on the Particle Size of Niosomes. Iran J Pharm Res. 2018;17:1–11. [PubMed] [PMC]

13.

Mowlaeifar MH, Niakousari M, Hosseini SMH, Eskandari MH. Effect of Cholesterol to Vitamin D3 and Span 60 to Tween 60 Ratios on the Characteristics of Niosomes: Variable Optimization Using Response Surface Methodology (RSM). J Food Qual. 2022;2022:7005531. [DOI]

14.

Zolghadri S, Asad AG, Farzi F, Ghajarzadeh F, Habibi Z, Rahban M, et al. Span 60/Cholesterol Niosomal Formulation as a Suitable Vehicle for Gallic Acid Delivery with Potent In Vitro Antibacterial, Antimelanoma, and Anti-Tyrosinase Activity. Pharmaceuticals (Basel). 2023;16:1680. [DOI] [PubMed] [PMC]

15.

Khaliq NU, Lee J, Kim S, Sung D, Kim H. Pluronic F-68 and F-127 Based Nanomedicines for Advancing Combination Cancer Therapy. Pharmaceutics. 2023;15:2102. [DOI] [PubMed] [PMC]

16.

Gao S, Sui Z, Jiang Q, Jiang Y. Functional Evaluation of Niosomes Utilizing Surfactants in Nanomedicine Applications. Int J Nanomedicine. 2024;19:10283–305. [DOI] [PubMed] [PMC]

17.

Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, et al. Niosome: A future of targeted drug delivery systems. J Adv Pharm Technol Res. 2010;1:374–80. [DOI] [PubMed] [PMC]